Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 5/20 | 0.44 |
| ▸ | FPR1 | P21462 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | IDH1 | O75874 | 2/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903128 | 1.00 | ROCK2 (0.50) | ROCK2ROCK1CDC42BPBARFPR1 | |
| SCHEMBL4896866 | 0.85 | AR (0.59) | ROCK2ROCK1CDC42BPBAR | |
| SCHEMBL4903955 | 0.85 | AR (0.59) | ROCK2ROCK1CDC42BPBAR | |
| SCHEMBL4904784 | 0.82 | AR (0.54) | AR | |
| SCHEMBL4901169 | 0.82 | AR (0.54) | AR | |
| SCHEMBL2938886 | 0.77 | CHRNB4 (0.46) | FPR1FPR2FFAR1IDH1SYK | |
| SCHEMBL12082307 | 0.77 | FFAR1 (0.56) | ROCK2ROCK1CDC42BPBFPR1FPR2 | |
| SCHEMBL12082229 | 0.77 | FFAR1 (0.56) | ROCK2ROCK1CDC42BPBFPR1FPR2 | |
| SCHEMBL13638851 | 0.76 | ADORA2A (0.45) | ROCK2ROCK1CDC42BPBFPR1FPR2 | |
| SCHEMBL2938534 | 0.76 | FFAR1 (0.43) | FPR1FPR2FFAR1IDH1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045504-A1 | Benzonitrile Derivatives to Treat Musculoskeletal Frailty | PFIZER PRODUCTS INC. (US) | 2008-02-21 | — | — | US | claimed |
| EP-1747193-A1 | BENZONITRILE DERIVATIVES TO TREAT MUSCULOSKELETAL FRAILTY | Pfizer Products Incorporated (US) | 2007-01-31 | — | — | EP | claimed |
| WO-2005108351-A1 | BENZONITRILE DERIVATIVES TO TREAT MUSCULOSKELETAL FRAILTY | PFIZER PRODUCTS INC. (US) | 2005-11-17 | — | — | WO | claimed |
| US-20080045504-A1 | Benzonitrile Derivatives to Treat Musculoskeletal Frailty | PFIZER PRODUCTS INC. (US) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045504-A1 | Benzonitrile Derivatives to Treat Musculoskeletal Frailty | TNNC1, TNNI3, TNNT2 | ROCK2 3373/4885ROCK1 2470/4885CDC42BPB 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.